

23 June 2016

Authority Meeting Report

1 Declarations of Interest

There were no conflicts of interest declared.

2 Health and Safety

There were no health and safety items to report.

3 Risk Management

It was noted that risk management had been discussed at the previous board meeting and that there were no updates for this meeting.

4 Chief Executive's Report

The Chief Executive provided an overview of the main highlights of her report which were noted by the Authority:

- The HPRA is considering establishing an innovation office to further support the pharma industry in Ireland.
- The medical devices legislation was passed at a European level and in relation to medical devices fees, the Statutory Instrument is being prepared by the Department of Health for implementation in 2017.
- With regard to Operation Pangea, the annual initiative which targets the illegal sale of internet prescription medicines, over 60,000 units of medication were detained in Ireland with close to 200 enforcement agencies taking part globally. The number of sedatives seized has reduced which is believed to be linked to the work the HPRA has done with An Garda Síochána.
- The Eolas project is continuing to progress well.
- In respect of international developments, the proposed review of centralised fees paid to the EMA and the National Competent Authorities (NCAs) is being reviewed by the European Commission. The Commission is engaging external consultants to help conduct the review.
- The HPRA's Veterinary Assessment Manager has been appointed Chair of the EMA's CVMP. The Chair extended congratulations on behalf of the Authority.

5 Authority Subgroup

The Authority discussed the future structure of the scientific advisory committees. It was agreed that the Authority set up a subgroup to consider the matter in more detail. The Chair of the Advisory Committee for Medical Devices and the Chief Executive are to report back at the next meeting of the Authority.

6 HR & Change Strategy

The Authority was provided with an overview of the proposed HR and Change strategy developed as a result of reviewing similar organisations, best practice in the HR sector and significant consultation with relevant stakeholders. The HR and Change strategy focuses on a number of strategic goals to assist in the delivery of the organisational strategy. It was noted that there would be ongoing monitoring and review of the strategy by the Management Committee with regular feedback to the Authority. The Authority was highly complimentary of the strategy and the work carried out to date.

7 Public Information Campaign

The Authority noted the public information campaign proposal to commence in October 2016. The 2016 campaign is to promote the safe and appropriate use of human medicines while raising HPRA brand awareness. It was also noted that the HPRA has won an award for excellence in public relations from the Public Relations Institute of Ireland for its seasonally based media campaigns for cosmetic products. The Authority was highly complimentary of this achievement and asked that congratulations be passed on to the Communications Manager and the team involved.

8 Financial

The management accounts for April 2016 were noted by the members and will be reviewed by the Audit Committee at its next meeting. The final Financial Statements following the C&AG audit were approved.

9 Licensing Activities

The tables of licences approved by the Management Committee during the period 06/05/16 to 10/06/16 were noted by the Authority.

10 Authority Meeting Dates 2016

The Authority noted the meeting dates for 2016.

11 HPRA Proposal to Host ICDRA 2018

The Authority was informed that the HPRA bid document for hosting the WHO International Coalition of Drug Regulatory Authorities (ICDRA) in 2018 has been prepared with the assistance of Fáilte Ireland. The bid was submitted to the WHO and hard copies of the proposal were to be sent to the Authority members following the meeting.